FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2788961298> ?p ?o ?g. }

• W2788961298 endingPage "9450" @default.
• W2788961298 startingPage "9440" @default.
• W2788961298 abstract "In Australia, 18% of the population, representing around one in five Australians, experience or are diagnosed with some form of arthritis. This equates to about 3.85 million Australians. The 2008 Crosby Textor Public Opinion Poll (Chong 2012) shows that Australians are more worried about developing arthritis than any other disease. The average cost in terms of arthritis treatment per person per year is $6200, with 61% of arthritis costs borne by the individuals themselves. Glucosamine is an over the-counter complementary medicine marketed for the treatment and relief of various types of arthritis; however, it is only clinically indicated for osteoarthritis. The existing research is conflicting regarding its efficacy. Aim: The aim of this study is to explore consumer perception of the efficacy of, and tolerance for, glucosamine preparations in inflammatory joint diseases. Method: The first component of the study was a qualitative observational survey based, with a 20-question survey administered to members of the community to capture their personal experience of the efficacy and toxicity of glucosamine. Survey questions were based on a visual pain and joint function scale. The second part of the study was an analysis based on an unidentifiable historical patient report to investigate if patients use glucosamine alone or with other medications indicated for the treatment of arthritis, what form of glucosamine salt was used, how long they have been using glucosamine and at what dose. Results: Out of 87 participants (aged 40–84 years, both male and female), 91.9% and 91.7% stated that glucosamine reduced their pain and improved their joint movement respectively. Pain was perceived to be reduced by 3–4 points (out of a possible 5 or more) in 46.5% of participants and 1–2 points’ improvement out of possible 5 or more in joint movement was found in 51.7% of participants. Sixty participants who used glucosamine for six months or more indicated a reduction in their pain and improvement in their joint function by at least 1 point on the scale ranging up to 5 points. The majority of the 60 participants who used glucosamine for six months or more indicated a pain improvement of 3–4 points on the scale. Six participants indicated that glucosamine was not effective in reducing their pain, and four participants indicated that it did not improve their joints function; those participants took glucosamine for less than six months. All others (n=17) had less significant improvement ( Discussion: This study provided insight on the possible benefits of glucosamine in relieving oxidative stress associated with arthritis, given its strong antioxidant activity. Critical analysis of the literature revealed that most studies that reported effectiveness of glucosamine used glucosamine sulphate whilst concluding that glucosamine was not effective when used in the hydrochloride formulation. Few studies investigated the effectiveness of glucosamine in other types of arthritis and no research has been conducted on the antioxidant activity of glucosamine in arthritis treatment. Conclusion: The results of this study indicate that health professionals have a degree of confidence in the benefits of glucosamine as a complementary treatment for osteoarthritis. Five out of 87 participants had rheumatoid arthritis and, whilst this is a small percentage of the total sample, they reported that it was effective. It is therefore recommended that further research be conducted on the efficacy of glucosamine in different types of arthritis and examining the antioxidant role of glucosamine given the oxidative stress associated with arthritis." @default.
• W2788961298 created "2018-03-06" @default.
• W2788961298 creator A5059591331 @default.
• W2788961298 creator A5060422758 @default.
• W2788961298 creator A5070725812 @default.
• W2788961298 date "2018-01-28" @default.
• W2788961298 modified "2023-09-26" @default.
• W2788961298 title "Consumers’ perception of the efficacy and tolerance of glucosamine in joint diseases" @default.
• W2788961298 cites W13785005 @default.
• W2788961298 cites W1493667447 @default.
• W2788961298 cites W1493918286 @default.
• W2788961298 cites W1498260807 @default.
• W2788961298 cites W1543298386 @default.
• W2788961298 cites W1678513801 @default.
• W2788961298 cites W1761300068 @default.
• W2788961298 cites W1812173421 @default.
• W2788961298 cites W1858962647 @default.
• W2788961298 cites W1895543855 @default.
• W2788961298 cites W1964407569 @default.
• W2788961298 cites W1968974073 @default.
• W2788961298 cites W1973320020 @default.
• W2788961298 cites W1974673393 @default.
• W2788961298 cites W1983052941 @default.
• W2788961298 cites W1995187962 @default.
• W2788961298 cites W1995763698 @default.
• W2788961298 cites W1997035556 @default.
• W2788961298 cites W2002066714 @default.
• W2788961298 cites W2014103815 @default.
• W2788961298 cites W2024415641 @default.
• W2788961298 cites W2033422116 @default.
• W2788961298 cites W2034146654 @default.
• W2788961298 cites W2035696265 @default.
• W2788961298 cites W2038963194 @default.
• W2788961298 cites W2040177459 @default.
• W2788961298 cites W2042074652 @default.
• W2788961298 cites W2044953211 @default.
• W2788961298 cites W2047143077 @default.
• W2788961298 cites W2049175836 @default.
• W2788961298 cites W2055083152 @default.
• W2788961298 cites W2055150344 @default.
• W2788961298 cites W2055291298 @default.
• W2788961298 cites W2058505385 @default.
• W2788961298 cites W2062814924 @default.
• W2788961298 cites W2063795634 @default.
• W2788961298 cites W2063966891 @default.
• W2788961298 cites W2064765003 @default.
• W2788961298 cites W2065621311 @default.
• W2788961298 cites W2069572429 @default.
• W2788961298 cites W2071491304 @default.
• W2788961298 cites W20719884 @default.
• W2788961298 cites W2079631924 @default.
• W2788961298 cites W2084518320 @default.
• W2788961298 cites W2085739946 @default.
• W2788961298 cites W2087492003 @default.
• W2788961298 cites W2091282223 @default.
• W2788961298 cites W2092174616 @default.
• W2788961298 cites W2100072795 @default.
• W2788961298 cites W2101840353 @default.
• W2788961298 cites W2106059946 @default.
• W2788961298 cites W2108718331 @default.
• W2788961298 cites W2113079259 @default.
• W2788961298 cites W2115409044 @default.
• W2788961298 cites W2115506640 @default.
• W2788961298 cites W2117549257 @default.
• W2788961298 cites W2122435770 @default.
• W2788961298 cites W2124790232 @default.
• W2788961298 cites W2126408248 @default.
• W2788961298 cites W2138176952 @default.
• W2788961298 cites W2142284380 @default.
• W2788961298 cites W2151251857 @default.
• W2788961298 cites W2155109530 @default.
• W2788961298 cites W2160902451 @default.
• W2788961298 cites W2161408419 @default.
• W2788961298 cites W2161739351 @default.
• W2788961298 cites W2167792025 @default.
• W2788961298 cites W2167814310 @default.
• W2788961298 cites W2171529323 @default.
• W2788961298 cites W2274722622 @default.
• W2788961298 cites W2299158212 @default.
• W2788961298 cites W2336588424 @default.
• W2788961298 cites W2405988120 @default.
• W2788961298 cites W2428009149 @default.
• W2788961298 cites W2440004558 @default.
• W2788961298 cites W24572364 @default.
• W2788961298 cites W26534214 @default.
• W2788961298 cites W60970192 @default.
• W2788961298 doi "https://doi.org/10.24327/ijcar.2018.9450.1562" @default.
• W2788961298 hasPublicationYear "2018" @default.
• W2788961298 type Work @default.
• W2788961298 sameAs 2788961298 @default.
• W2788961298 citedByCount "0" @default.
• W2788961298 crossrefType "journal-article" @default.
• W2788961298 hasAuthorship W2788961298A5059591331 @default.
• W2788961298 hasAuthorship W2788961298A5060422758 @default.
• W2788961298 hasAuthorship W2788961298A5070725812 @default.
• W2788961298 hasConcept C126322002 @default.
• W2788961298 hasConcept C142724271 @default.
• W2788961298 hasConcept C15744967 @default.

• next